» Articles » PMID: 20054141

Pulmonary Surfactant: an Immunological Perspective

Overview
Date 2010 Jan 8
PMID 20054141
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary surfactant has two crucial roles in respiratory function; first, as a biophysical entity it reduces surface tension at the air water interface, facilitating gas exchange and alveolar stability during breathing, and, second, as an innate component of the lung's immune system it helps maintain sterility and balance immune reactions in the distal airways. Pulmonary surfactant consists of 90% lipids and 10% protein. There are four surfactant proteins named SP-A, SP-B, SP-C, and SP-D; their distinct interactions with surfactant phospholipids are necessary for the ultra-structural organization, stability, metabolism, and lowering of surface tension. In addition, SP-A and SP-D bind pathogens, inflict damage to microbial membranes, and regulate microbial phagocytosis and activation or deactivation of inflammatory responses by alveolar macrophages. SP-A and SP-D, also known as pulmonary collectins, mediate microbial phagocytosis via SP-A and SP-D receptors and the coordinated induction of other innate receptors. Several receptors (SP-R210, CD91/calreticulin, SIRPalpha, and toll-like receptors) mediate the immunological functions of SP-A and SP-D. However, accumulating evidence indicate that SP-B and SP-C and one or more lipid constituents of surfactant share similar immuno-regulatory properties as SP-A and SP-D. The present review discusses current knowledge on the interaction of surfactant with lung innate host defense.

Citing Articles

The Therapeutic Potential of Myo-Inositol in Managing Patients with Respiratory Diseases.

Quecchia C, Vianello A Int J Mol Sci. 2025; 26(5).

PMID: 40076806 PMC: 11901072. DOI: 10.3390/ijms26052185.


The Immune Modulatory Role of Surfactants in Infection.

Li X, Zeng Q, Liu C, Yi X, Luo H, Tong Q J Inflamm Res. 2025; 18:2909-2922.

PMID: 40034686 PMC: 11873027. DOI: 10.2147/JIR.S507526.


Origin and stepwise evolution of vertebrate lungs.

Li Y, Hu M, Zhang Z, Wu B, Zheng J, Zhang F Nat Ecol Evol. 2025; .

PMID: 39953253 DOI: 10.1038/s41559-025-02642-6.


Cutting-edge perspectives on biosurfactants: implications for antimicrobial and biomedical applications.

Gupta K, Sharma V 3 Biotech. 2024; 14(12):297.

PMID: 39539528 PMC: 11554964. DOI: 10.1007/s13205-024-04146-9.


Association between dietary choline intake and asthma and pulmonary inflammation and lung function: NHANES analysis 2009-2018.

Ding Q, Hao T, Gao Y, Jiang S, Huang Y, Liang Y J Health Popul Nutr. 2024; 43(1):143.

PMID: 39252146 PMC: 11386084. DOI: 10.1186/s41043-024-00635-y.


References
1.
Ikegami M, Na C, Korfhagen T, Whitsett J . Surfactant protein D influences surfactant ultrastructure and uptake by alveolar type II cells. Am J Physiol Lung Cell Mol Physiol. 2004; 288(3):L552-61. DOI: 10.1152/ajplung.00142.2004. View

2.
Hoth J, Wells J, Brownlee N, Hiltbold E, Meredith J, McCall C . Toll-like receptor 4-dependent responses to lung injury in a murine model of pulmonary contusion. Shock. 2008; 31(4):376-81. PMC: 2918369. DOI: 10.1097/SHK.0b013e3181862279. View

3.
Tsai R, Discher D . Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008; 180(5):989-1003. PMC: 2265407. DOI: 10.1083/jcb.200708043. View

4.
Wright J, Youmans D . Degradation of surfactant lipids and surfactant protein A by alveolar macrophages in vitro. Am J Physiol. 1995; 268(5 Pt 1):L772-80. DOI: 10.1152/ajplung.1995.268.5.L772. View

5.
Kuronuma K, Mitsuzawa H, Takeda K, Nishitani C, Chan E, Kuroki Y . Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2. J Biol Chem. 2009; 284(38):25488-500. PMC: 2757950. DOI: 10.1074/jbc.M109.040832. View